Last reviewed 2026-05-26 · How we verify

Xenbilox

Institut National de la Santé Et de la Recherche Médicale, France · Phase 2 active Small molecule ✓ Verified May 2026

Xenbilox is a Small molecule drug developed by Institut National de la Santé Et de la Recherche Médicale, France. It is currently in Phase 2 development. Also known as: Chenodeoxycholic acid.

Xenbilox is a small molecule that acts as a bile acid receptor FXR agonist. It is being studied in clinical trials for the treatment of hereditary spastic paraplegia.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Xenbilox
Also known as	Chenodeoxycholic acid
Sponsor	Institut National de la Santé Et de la Recherche Médicale, France
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5 (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Xenbilox CI brief — competitive landscape report
Xenbilox updates RSS · CI watch RSS
Institut National de la Santé Et de la Recherche Médicale, France portfolio CI

Frequently asked questions about Xenbilox

What is Xenbilox?

Xenbilox is a Small molecule drug developed by Institut National de la Santé Et de la Recherche Médicale, France.

Who makes Xenbilox?

Xenbilox is developed by Institut National de la Santé Et de la Recherche Médicale, France (see full Institut National de la Santé Et de la Recherche Médicale, France pipeline at /company/institut-national-de-la-sant-et-de-la-recherche-m-dicale-france).

Is Xenbilox also known as anything else?

Xenbilox is also known as Chenodeoxycholic acid.

What development phase is Xenbilox in?

Xenbilox is in Phase 2.

Manufacturer: Institut National de la Santé Et de la Recherche Médicale, France — full pipeline
Therapeutic area: All drugs in Other
Also known as: Chenodeoxycholic acid

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing